PriceTargets.com logo

Verrica Pharmaceuticals - VRCA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.50
  • Forecasted Upside: 1,257.14%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.70 As of 12/17/2024 01:00 AM ET
▼ -0.02 (-2.78%)

This chart shows the closing price for VRCA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verrica Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRCA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRCA

Analyst Price Target is $9.50
▲ +1,257.14% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Verrica Pharmaceuticals in the last 3 months. The average price target is $9.50, with a high forecast of $14.00 and a low forecast of $2.00. The average price target represents a 1,257.14% upside from the last price of $0.70.

This chart shows the closing price for VRCA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Verrica Pharmaceuticals. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/6/2024HC WainwrightDowngradeBuy ➝ Neutral
11/5/2024Needham & Company LLCReiterated RatingHold
11/5/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $2.00
10/21/2024TD CowenLower TargetBuy ➝ Buy$15.00 ➝ $10.00
10/4/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$13.00 ➝ $11.00
10/3/2024Needham & Company LLCReiterated RatingBuy ➝ Hold$12.00
10/2/2024Brookline Capital ManagementReiterated RatingBuy ➝ Hold
8/15/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$14.00 ➝ $13.00
8/15/2024Needham & Company LLCLower TargetBuy ➝ Buy$16.00 ➝ $12.00
5/14/2024Needham & Company LLCBoost TargetBuy ➝ Buy$8.00 ➝ $16.00
5/14/2024HC WainwrightBoost TargetBuy ➝ Buy$13.00 ➝ $14.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
3/1/2024HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00
12/15/2023Jefferies Financial GroupReiterated RatingBuy ➝ Buy$10.00
11/10/2023Needham & Company LLCLower TargetBuy ➝ Buy$10.00 ➝ $8.00
10/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
8/23/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
7/27/2023HC WainwrightBoost TargetBuy$11.00 ➝ $12.00
7/25/2023Royal Bank of CanadaBoost TargetOutperform$11.00 ➝ $14.00
7/25/2023Needham & Company LLCUpgradeHold ➝ Buy$10.00
3/22/2023Jefferies Financial GroupInitiated CoverageBuy$10.00
3/7/2023Royal Bank of CanadaReiterated RatingOutperform$11.00
2/13/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$11.00
8/15/2022HC WainwrightLower Target$11.00
6/29/2022HC WainwrightReiterated RatingBuy$12.00
5/31/2022HC WainwrightLower TargetBuy$20.00 ➝ $12.00
5/25/2022Needham & Company LLCDowngradeBuy ➝ Hold
5/25/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$16.00 ➝ $4.00
3/10/2022Brookline Capital ManagementReiterated RatingBuy
3/10/2022Brookline Capital AcquisitionInitiated CoverageBuy$20.00
3/7/2022HC WainwrightReiterated RatingBuy
3/3/2022Needham & Company LLCLower TargetBuy$20.00 ➝ $18.00
11/30/2021HC WainwrightReiterated RatingBuy$19.00
11/23/2021Royal Bank of CanadaReiterated RatingBuy$16.00
9/22/2021HC WainwrightReiterated RatingBuy$24.00 ➝ $20.00
9/21/2021Jefferies Financial GroupReiterated RatingBuy$20.00
9/21/2021Needham & Company LLCLower TargetPositive ➝ Buy$22.00 ➝ $20.00
9/21/2021Royal Bank of CanadaLower TargetOutperform$19.00 ➝ $16.00
6/1/2021Northland SecuritiesLower TargetOutperform$24.00 ➝ $19.00
5/13/2021Royal Bank of CanadaInitiated CoverageOutperform$19.00
5/10/2021Needham & Company LLCReiterated RatingBuy$22.00
4/14/2021Needham & Company LLCReiterated RatingBuy$22.00
3/8/2021HC WainwrightBoost TargetBuy$21.00 ➝ $24.00
12/24/2020HC WainwrightReiterated RatingBuy$18.00 ➝ $21.00
7/24/2020Northland SecuritiesReiterated RatingBuy$15.00
7/15/2020Bank of AmericaDowngradeBuy ➝ Neutral$17.00 ➝ $10.00
6/30/2020HC WainwrightLower TargetBuy$24.00 ➝ $18.00
6/30/2020Needham & Company LLCLower TargetBuy$20.00 ➝ $17.00
6/24/2020Northland SecuritiesInitiated CoverageOutperform$21.00
5/18/2020HC WainwrightReiterated RatingBuy$24.00
4/16/2020Needham & Company LLCReiterated RatingBuy$20.00
3/23/2020Needham & Company LLCInitiated CoverageBuy$20.00
3/17/2020HC WainwrightReiterated RatingBuy
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Verrica Pharmaceuticals logo
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Read More

Today's Range

Now: $0.70
Low: $0.67
High: $0.73

50 Day Range

MA: $1.16
Low: $0.70
High: $1.68

52 Week Range

Now: $0.70
Low: $0.67
High: $11.41

Volume

433,211 shs

Average Volume

493,212 shs

Market Capitalization

$31.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Verrica Pharmaceuticals?

The following sell-side analysts have issued research reports on Verrica Pharmaceuticals in the last year: Brookline Capital Management, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, and TD Cowen.
View the latest analyst ratings for VRCA.

What is the current price target for Verrica Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Verrica Pharmaceuticals in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 1,257.1%. HC Wainwright has the highest price target set, predicting VRCA will reach $14.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $2.00 for Verrica Pharmaceuticals in the next year.
View the latest price targets for VRCA.

What is the current consensus analyst rating for Verrica Pharmaceuticals?

Verrica Pharmaceuticals currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRCA, but not buy more shares or sell existing shares.
View the latest ratings for VRCA.

What other companies compete with Verrica Pharmaceuticals?

Other companies that are similar to Verrica Pharmaceuticals include Vaxart, Cabaletta Bio, InflaRx, Neoleukin Therapeutics and Protalix BioTherapeutics. Learn More about companies similar to Verrica Pharmaceuticals.

How do I contact Verrica Pharmaceuticals' investor relations team?

Verrica Pharmaceuticals' physical mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company's listed phone number is (434) 453-3300 and its investor relations email address is [email protected]. The official website for Verrica Pharmaceuticals is www.verrica.com. Learn More about contacing Verrica Pharmaceuticals investor relations.